CD Biosynsis offers high-efficiency Mammalian Cells Gene Knockout Services, providing permanent and precise deletion or disruption of target genes in hosts like CHO (Chinese Hamster Ovary) cells and HEK293 cells. Gene knockout is a foundational step in host cell engineering, utilized primarily to eliminate undesirable host functions, such as native proteases, pro-apoptotic pathways, or enzymes involved in non-human glycosylation pathways. Leveraging the precision of CRISPR-Cas9 to induce double-strand breaks (DSBs), our services rely on the cell's Non-Homologous End Joining (NHEJ) pathway to generate stable, multi-allelic, loss-of-function mutations (indels). We provide end-to-end solutions, from gRNA design to final clone screening, accelerating the development of superior mammalian cell lines with enhanced specific productivity (Qp), extended culture viability, and tailored product quality for biotherapeutics.
Get a QuoteGene knockout in mammalian cells is utilized to resolve major bioproduction limitations: apoptosis, protein degradation, and undesirable glycosylation. Our CRISPR-Cas9 platform is optimized to address this by focusing on high-efficiency, multiplex delivery of the editing machinery (RNP or optimized vector). Cas9 induces a double-strand break (DSB) at the target locus, which the cell typically repairs via the error-prone Non-Homologous End Joining (NHEJ) pathway. This repair often results in frameshift mutations (insertions or deletions, or indels) that functionally disrupt the gene. This strategy is critical for removing genes that negatively impact cell viability (e.g., Bax, Bak) or product quality (e.g., alpha(1,3)-galactosyltransferase).
Locus Disruption Design
Design of gRNA(s) targeting the early coding sequence to maximize the chance of frame-shift mutations (indels) that disrupt the functional protein product, ensuring complete loss-of-function across all alleles.
Multi-Allelic Knockout
Utilization of highly active Cas9 and multiplex gRNA to simultaneously disrupt all alleles of a gene (critical in polyploid CHO cells) to achieve a definitive functional knockout.
Indel Verification Primers
Design of robust PCR and sequencing primers spanning the gRNA cut site for definitive, clone-level verification of successful indel formation using TIDE analysis or deep sequencing.
RNP Delivery System
Preference for Ribonucleoprotein (RNP) complexes (Cas9 protein + gRNA) for transient, high-efficiency, and low off-target delivery into mammalian cells via electroporation.
Lentivirus/Plasmid Delivery
Used for stable cell line generation requiring integrated Cas9 or for hard-to-transfect cell lines, ensuring a robust source of the editing machinery.
Selection Marker Strategy
Use of co-transfected selection markers or reporter genes to enrich for the cell population that has undergone the desired editing event, streamlining clonal isolation.
Glycosylation Pathway Control
Deletion of key glycosylation enzymes (e.g., FUT8, GALT) to eliminate or reduce undesirable PTMs, such as increasing ADCC or removing immunogenic epitopes.
Anti-Apoptosis Engineering
Disruption of pro-apoptotic genes (e.g., Bax, Bak) to extend the cell viability window under industrial stress, leading to higher final volumetric titer.
Byproduct & Protease Control
Knockout of metabolic enzymes (e.g., LDHA) to reduce toxic byproducts (lactate) or deletion of host proteases to minimize product degradation.
A systematic process for achieving precise disruption and stable clone isolation.
1. Rational Design & RNP Preparation
2. Transfection & Selection
3. Single Cell Cloning & Screening
4. Clone Verification & Delivery
Identify target gene(s) and all relevant alleles. Design and synthesize high-specificity gRNA(s) targeting the early coding region.
Prepare the Cas9 enzyme/gRNA Ribonucleoprotein (RNP) complex for transient, high-titer delivery.
Design primers for verification of indel formation (TIDE/Sanger/Deep Sequencing) at the target locus.
Deliver the RNP complex (and selection marker) into the mammalian host cell line via optimized protocols.
Culture cells to allow the NHEJ repair pathway to finalize the genomic edit.
Apply antibiotic selection or FACS sorting to enrich for edited clones.
Genotype verification via sequencing of the edited locus(i) to confirm multi-allelic indel formation.
Phenotypic validation of the final clone's functional stability (titer, quality) over multiple passages.
Delivery of the verified Master Cell Bank (MCB) and complete documentation.
Multi-Allelic KO Efficiency
Optimized multiplex strategies overcome the challenge of multi-allelic deletion in polyploid hosts like CHO, ensuring complete functional knockout.
Enhanced ADCC & Efficacy
Targeted deletion of FUT8 eliminates core fucose, significantly enhancing the Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) of therapeutic antibodies.
Maximized Culture Viability
Permanent disruption of pro-apoptotic genes ensures cell fitness under high-stress bioreactor conditions, directly boosting volumetric titer.
Reduced Byproducts
Knockout of metabolic shunts (e.g., LDHA) redirects carbon flux for energy efficiency, minimizing the accumulation of toxic lactate and ammonia.
1. Why is multi-allelic knockout necessary in CHO cells?
CHO cells have a pseudo-tetraploid genome, meaning many genes have multiple functional alleles. To achieve a complete loss-of-function (e.g., eliminating all FUT8 activity), all alleles must be disrupted simultaneously.
2. How does FUT8 knockout enhance therapeutic antibodies?
FUT8 knockout eliminates core fucose from N-glycans on the Fc region of an antibody. This modification significantly increases the antibody's binding affinity to the FcgRIIIa receptor on immune cells, leading to enhanced ADCC (Antibody-Dependent Cell-mediated Cytotoxicity).
3. What is the role of NHEJ in mammalian gene knockout?
NHEJ (Non-Homologous End Joining) is the most utilized repair pathway. It is error-prone, generating insertions or deletions (indels) that cause a frameshift, functionally disrupting the target gene, which is the desired outcome for a knockout.
4. How does anti-apoptosis engineering increase titer?
By disrupting pro-apoptotic genes (like Bax or Bak), the host cell resists programmed cell death induced by bioreactor stress (nutrient depletion, waste accumulation), extending the viable, high-production phase and maximizing final volumetric titer.
5. How is the final knockout clone verified at the genomic level?
Verification is done through sequencing methods (TIDE analysis, Sanger sequencing) to confirm disruptive indels at the target locus. For multi-allelic knockouts, deep sequencing is often used to ensure all alleles are successfully modified.
6. What delivery methods are used for CRISPR-Cas9 in mammalian cells?
We primarily use optimized electroporation or lipofection to deliver the highly efficient RNP complex (Cas9 protein + gRNA) for transient editing, minimizing off-target effects and toxicity.
7. What input is required to start a gene knockout project?
We require the specific mammalian host cell line (e.g., CHO-K1, HEK293) and the accession number or sequence of the target gene(s) to be disrupted.
8. Can you combine gene knockout with gene knock-in?
Yes. A common strategy involves using gene knockout (e.g., FUT8 KO) to create an optimized chassis, followed by a separate CRISPR/HDR Gene Knock-in service to integrate the therapeutic gene into a highly expressed genomic safe harbor locus.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.